Rybrevant (Amivantamab-Vmjw) for Lung Cancer

Overview
Rybrevant, approved by the U.S. Food and Drug Administration (FDA), is a targeted therapy for the treatment of lung cancer. It is specifically indicated for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as identified by an FDA-approved test. This indication covers its use both as a single agent and in combination with the chemotherapy drugs carboplatin and pemetrexed for first-line treatment.

Rybrevant is also known by its drug name, amivantamab-vmjw.

Amivantamab-vmjw belongs to the category of antineoplastic agents, specifically as a bispecific antibody targeting both the EGF and MET receptors. This dual targeting is thought to interrupt the growth signaling pathways that are overactive in certain types of lung cancers, thereby inhibiting tumor growth and spread.

How do I take it?
Rybrevant is administered through an intravenous infusion, with the dosage based on the recipient’s baseline body weight. The drug is initially given weekly for four weeks, with the first dose split between two days in the first week. 

For those receiving Rybrevant in combination with chemotherapy, the treatment continues every three weeks starting at week 7. 

When administered as a single agent, the treatment shifts to every two weeks starting at week 5. Premedications are sometimes recommended to manage potential side effects. This medication should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Rybrevant include rash, paronychia (nail inflammation), musculoskeletal pain, dyspnea (shortness of breath), nausea, fatigue, edema (swelling due to trapped fluid), stomatitis (inflammation or soreness of the mouth), cough, constipation, and vomiting. When used in combination with carboplatin and pemetrexed, other common effects may occur.

Rare but serious side effects may include infusion-related reactions; interstitial lung disease (ILD)/pneumonitis; severe dermatologic (skin) reactions; ocular (eye-related) toxicity; and harm to an unborn fetus. 

For more information about this treatment, visit:

Rybrevant (Amivantamab-Vmjw) Injection, for Intravenous Use — U.S. Food and Drug Administration